Artivion (NYSE: AORT) SVP gets stock award, sells shares for tax

Rhea-AI Filing Summary

ARTIVION, INC. senior vice president Stanton Marshall S. reported two stock transactions involving company common shares. He acquired 21,838 shares on a grant/award basis at $0.0000 per share as part of performance stock units granted in February 2025. According to the award terms, additional portions of this grant are eligible to vest on February 28, 2027 and February 28, 2028, subject to continued employment on each vesting date. On March 3, 2026, 2,149 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations through a sell-to-cover transaction, which the company notes was not a discretionary sale. After these transactions, Marshall directly owned 60,097 shares of Artivion common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stanton Marshall S.

(Last) (First) (Middle)

1655 ROBERTS BLVD., NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical & MD Affair

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		21,838(1)	A	$0	62,246	D
Common Stock	03/03/2026		S		2,149(2)	D	$37.7756	60,097	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date.

2. These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

Remarks:

	/s/ Marshall Stanton	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Artivion (AORT) SVP Stanton Marshall report?

Stanton Marshall reported receiving a stock award and selling shares to cover taxes. He acquired 21,838 Artivion common shares from a performance stock unit grant and sold 2,149 shares in a sell-to-cover transaction, remaining a direct owner of 60,097 shares.

How many Artivion (AORT) shares did the SVP sell, and at what price?

The SVP sold 2,149 Artivion common shares at an average price of $37.7756 per share. The filing states this sale occurred on March 3, 2026 and was executed solely to satisfy tax withholding obligations tied to vesting performance stock units.

Why were Artivion (AORT) shares sold by the SVP in this Form 4?

The shares were sold to pay tax withholding obligations from vesting performance stock units. The company explains this was a “sell to cover” transaction, meaning shares were automatically sold to fund taxes and the sale did not represent a discretionary trading decision.

What stock award did the Artivion (AORT) SVP receive in this filing?

He received 21,838 shares of Artivion common stock through a grant linked to performance stock units awarded in February 2025. One-third vested and was issued on March 2, 2026, with the remaining portions eligible to vest in 2027 and 2028, subject to employment requirements.

What is Stanton Marshall’s Artivion (AORT) share ownership after these transactions?

Following the reported grant and tax-related sale, Stanton Marshall directly owns 60,097 Artivion common shares. This total reflects the issuance of shares from the performance stock unit award and the simultaneous sale of a portion of vested shares to satisfy associated tax withholding.

When will the remaining Artivion (AORT) performance stock units for the SVP vest?

The remaining shares from the February 2025 performance stock unit grant are eligible to vest in two equal parts. One-third may vest on February 28, 2027, and another third on February 28, 2028, assuming the SVP remains employed on each vesting date.